Anthropometric data of 14 patients with mucopolysaccharidosis I: Retrospective analysis and efficacy of recombinant human α-l-iduronidase (laronidase)
- 27 August 2009
- journal article
- clinical trial
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 99 (1) , 10-17
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis IPediatrics, 2009
- Mechanism of Glycosaminoglycan-Mediated Bone and Joint DiseaseThe American Journal of Pathology, 2008
- The MPS I registry: Design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type IMolecular Genetics and Metabolism, 2007
- Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I)Current Opinion in Rheumatology, 2005
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)The Journal of Pediatrics, 2004
- Can mucopolysaccharidosis type I disease severity be predicted based on a patient’s genotype? A comprehensive review of the literatureGenetics in Medicine, 2003
- Enzyme-Replacement Therapy in Mucopolysaccharidosis INew England Journal of Medicine, 2001
- Impaired Elastogenesis in Hurler DiseaseThe American Journal of Pathology, 2000
- The clinical spectrum of α‐L‐iduronidase deficiencyAmerican Journal of Medical Genetics, 1985
- A review and selection of simple laboratory methods used for the study of glycosaminoglycan excretion and the diagnosis of the mucopolysaccharidoses.Journal of Clinical Pathology, 1976